The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients.
Jean Jacques Grob
Consultant or Advisory Role - Roche
Honoraria - Roche
Rainer Kunstfeld
Consultant or Advisory Role - Roche
Honoraria - Roche
Brigitte Dreno
Consultant or Advisory Role - Roche
Thomas Jouary
Consultant or Advisory Role - Roche
Honoraria - Roche
Expert Testimony - Roche
Other Remuneration - Roche
Laurent Mortier
Consultant or Advisory Role - Roche/Genentech
Nicole Basset-Seguin
Consultant or Advisory Role - Roche
Honoraria - Roche
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; MedImmune; MSD; Novartis; Roche/Genentech
Honoraria - Bristol-Myers Squibb; MSD; Roche/Genentech
Johan Hansson
Research Funding - Roche
Lada Mitchell
Employment or Leadership Position - Roche
Michal Starnawski
Employment or Leadership Position - Roche
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche